Stockscreener 앱 받기
3.71
1.86%
-0.06
전일 마감가:
$3.77
열려 있는:
$3.73
하루 거래량:
343.10K
Relative Volume:
0.90
시가총액:
$208.88M
수익:
$68.68M
순이익/손실:
$-60.84M
주가수익비율:
-2.3188
EPS:
-1.6
순현금흐름:
$-38.42M
1주 성능:
-28.71%
1개월 성능:
-45.27%
6개월 성능:
-47.96%
1년 성능:
-62.32%
1일 변동 폭
$3.37
$3.765
1주일 범위
$3.37
$5.459
52주 변동 폭
$3.37
$10.01
풀몬스 Stock (LUNG) Company Profile
명칭
Pulmonx Corp
전화
650-364-0400
주소
700 CHESAPEAKE DRIVE, REDWOOD CITY
LUNG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LUNG
Pulmonx Corp
|
3.715 | 208.88M | 68.68M | -60.84M | -38.42M | -1.60 |
|
ABT
Abbott Laboratories
|
132.26 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.53 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.50 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.38 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.37 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
풀몬스 Stock (LUNG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-10 | 개시 | D. Boral Capital | Buy |
| 2024-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-06-04 | 개시 | Lake Street | Buy |
| 2024-02-23 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-09-05 | 개시 | Craig Hallum | Buy |
| 2023-02-27 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-12-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-07-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2021-12-08 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-04-01 | 개시 | Citigroup | Buy |
| 2021-03-25 | 개시 | Piper Sandler | Neutral |
| 2021-03-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-10-26 | 개시 | BofA Securities | Buy |
| 2020-10-26 | 개시 | Canaccord Genuity | Buy |
| 2020-10-26 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-10-26 | 개시 | Stifel | Buy |
| 2020-10-26 | 개시 | Wells Fargo | Equal Weight |
모두보기
풀몬스 주식(LUNG)의 최신 뉴스
Stifel maintains Buy on Pulmonx stock with $16 target By Investing.com - Investing.com India
Canaccord Genuity Group Lowers Pulmonx (NASDAQ:LUNG) Price Target to $15.00 - Defense World
Pulmonx Corp SEC 10-Q Report - TradingView
Pulmonx Corp (NASDAQ: LUNG) Loss Of -10.08% Compared To 52-Week Low; YTD Fall -44.48% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel
Pulmonx Corp (LUNG) Stock: A Year of Market Movement, Down and Up - investchronicle.com
In the Green: Pulmonx Corp (LUNG) Closes at 3.77, Up/Down -21.95 from Previous Day - DWinneX
Canaccord cuts Pulmonx stock target to $15, maintains Buy rating By Investing.com - Investing.com Nigeria
Pulmonx (LUNG) Price Target Lowered by Canaccord Genuity | LUNG Stock News - GuruFocus
Leading Lung Disease Treatment Pioneer Pulmonx Takes Stage at Bank of America Healthcare Conference - Stock Titan
Pulmonx (LUNG): Analyst Lowers Price Target, Maintains Overweigh - GuruFocus
Pulmonx (LUNG) Maintains "Buy" Rating with Stable Price Target | - GuruFocus
Canaccord cuts Pulmonx stock target to $15, maintains Buy rating - Investing.com
Pulmonx (LUNG) Receives Target Price Adjustment from Canaccord | - GuruFocus
Pulmonx (LUNG) Target Price Adjusted by Piper Sandler Analyst | - GuruFocus
Pulmonx Corp (LUNG) Q1 2025 Earnings Call Highlights: Strong International Growth Amid Domestic ... - Yahoo Finance
BlackRock, Inc. Reduces Stake in Pulmonx Corp: Analyzing the Imp - GuruFocus
Earnings call transcript: Pulmonx beats EPS forecast despite revenue miss in Q1 2025 - Investing.com Nigeria
Pulmonx Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Pulmonx earnings beat by $0.03, revenue topped estimates - Investing.com
LUNG Reports Strong Q1 Revenue, Surpasses Expectations | LUNG St - GuruFocus
Pulmonx Corp (LUNG) Q1 2025 Earnings: EPS Loss of $0.36 Beats Es - GuruFocus
Pulmonx (LUNG) Reaffirms 2025 Revenue and Expense Projections | - GuruFocus
Pulmonx (LUNG) Reaffirms 2025 Revenue and Expense Projections | LUNG Stock News - GuruFocus
Pulmonx Co. (NASDAQ:LUNG) Shares Purchased by Renaissance Technologies LLC - Defense World
Geode Capital Management LLC Purchases 9,454 Shares of Pulmonx Co. (NASDAQ:LUNG) - Defense World
Pulmonx Co. (NASDAQ:LUNG) Shares Sold by Russell Investments Group Ltd. - Defense World
Pulmonx Co. (NASDAQ:LUNG) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Pulmonx stock plunges to 52-week low of $5.38 amid market challenges - Investing.com Nigeria
Vanguard Group Inc. Grows Stock Holdings in Pulmonx Co. (NASDAQ:LUNG) - Defense World
Pulmonx stock plunges to 52-week low, hitting 4.71 USD By Investing.com - Investing.com Canada
Pulmonx stock plunges to 52-week low, hitting 4.71 USD - Investing.com Australia
Leading Lung Treatment Innovator Pulmonx Announces Q1 2025 Earnings Date - Stock Titan
American Century Companies Inc. Grows Stock Position in Pulmonx Co. (NASDAQ:LUNG) - Defense World
151,200 Shares in Pulmonx Co. (NASDAQ:LUNG) Acquired by Norges Bank - Defense World
Pulmonx Corp’s Banking’s 100-Day Moving Average at 6.80: Will the Stock Break Through? - investchronicle.com
Pulmonx stock plunges to 52-week low of $5.38 amid market challenges By Investing.com - Investing.com South Africa
Charles Schwab Investment Management Inc. Boosts Holdings in Pulmonx Co. (NASDAQ:LUNG) - Defense World
Pulmonx Co. (NASDAQ:LUNG) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Connor Clark & Lunn Investment Management Ltd. Buys 25,988 Shares of Pulmonx Co. (NASDAQ:LUNG) - Defense World
Insider Sell Alert: French Glendon E. III Sells 20,000 Shares of Pulmonx Corp (LUNG) - GuruFocus
Pulmonx corp director Glendon French sells $157,000 in stock By Investing.com - Investing.com Canada
Pulmonx corp director Glendon French sells $157,000 in stock - Investing.com
Canaccord maintains Buy rating on Pulmonx stock with $16 target By Investing.com - Investing.com Australia
Canaccord maintains Buy rating on Pulmonx stock with $16 target - Investing.com
Boral Capital sets Pulmonx stock Buy rating, $17 target - Investing.com India
Boral Capital sets Pulmonx stock Buy rating, $17 target By Investing.com - Investing.com South Africa
풀몬스 (LUNG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10.27%
0.14%
자본화:
|
볼륨(24시간):